Cempra Inc. (CEMP) announced Thursday morning that it has received a Complete Response Letter from the FDA for its new drug applications for oral and intravenous solithromycin. The drug was being developed for the treatment of community-acquired bacterial pneumonia in adults.
from RTT - Before the Bell http://ift.tt/2hw7kA9
via IFTTT
No comments:
Post a Comment